PannTheraPi
Life changing doe patients suffering from neurological diseases. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
$2—3m (Dealroom.co estimates Dec 2022.)
Company register number 895315877
Nimes Occitanie (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
€50.0k | Seed | ||
€400k | Grant | ||
€500k | Seed | ||
€500k | Convertible | ||
* | €2.5m | Grant | |
* | N/A | Series A | |
Total Funding | $4.3m |
Recent News about PannTheraPi
EditMore about PannTheraPi
EditPannTheraPi is the first pharmaceutical company dedicated to the development of Pannexin 1 channel blocker drugs for the treatment of brain and nervous diseases, aiming for better efficacy and better tolerance than current drugs.
PannTheraPi offers breakthrough innovation for the two main issues in development of current drugs in neurological diseases:
- Innovative target adressing the root cause of the diseases
- Representative non-clinical model using human brain tissues
PanTheraPi generates repurposed and new chemical entities drugs.
Keywords: Pharmaceuticals and Biotechnology, Brain Disease, Nervous Disease, Neurological Disease, Novel Therapies, Pharmaceutical Company, Pharmaceutical Data.